Company Overview

Vivo Bio Tech Limited, a contract research organization (CRO) in the pharmaceuticals and biotechnology sector, reported its financial results for FY 2025-26 and submitted its Annual Report along with notice for its 39th Annual General Meeting scheduled for September 30, 2026.

Financial Performance

Consolidated Results:

  • Revenue from operations: ₹53.33 crore (+14.3% YoY)
  • Net loss: ₹1.71 crore (vs. ₹7.28 crore profit in FY25)
  • Profit before tax: ₹4.81 crore (vs. ₹8.79 crore in FY25)
  • Tax expense: ₹6.52 crore (including deferred tax charge of ₹5.71 crore)
  • Basic EPS: (₹0.82) loss per share (vs. ₹4.76 profit in FY25)

Standalone Results:

  • Revenue from operations: ₹52.57 crore (+12.6% YoY)
  • Net loss: ₹1.94 crore (vs. ₹7.57 crore profit in FY25)
  • Total assets: ₹174.86 crore (+23.8% YoY)
  • Capital expenditure: ₹37.44 crore (+68% YoY)

Operational Highlights

The company achieved several operational milestones including GLP certification for its canine facility, import of breeder Beagles from Ridglan Farms, USA, and addition of six new contracts worth ₹19.83 crore with clients including NATCO, Microcrispr, Rygen, NNB Nutraceuticals, Lab4Life and Dabur. The company completed 1,388 studies during the year with capacity utilization remaining above 90%.

Capital Structure & Investments

Equity share capital increased from ₹17.16 crore to ₹22.19 crore due to conversion of 50,25,812 warrants into equity shares. The company made a significant non-current investment of ₹21.91 crore in Virinchi Limited, comprising ₹14.28 crore for 51,00,000 shares and ₹7.63 crore for 1,09,00,002 warrants.

AGM Agenda

The 39th AGM will consider adoption of audited financial statements, re-appointment of Mr. Kalyan Ram Mangipudi, and re-appointment of Mr. Sri Kalyan Kompella and Dr. Sankaranarayana Alangudi as Whole-time Directors with specified remuneration terms.

Subsidiary Performance

All four wholly-owned subsidiaries reported modest revenues between ₹18.79-19.89 lakh and profits between ₹4.12-7.66 lakh: Vivo Bio Labs Private Limited, Vivo Bio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited, and Vivo Bio Consulting Services Private Limited.

Regulatory Compliance & Accreditations

The company maintained multiple accreditations including OECD GLP (valid until June 2029), AAALACi (valid until March 2029), CPCSEA (valid until December 2026), ISO 9001:2015 (valid until January 2028), and SENAVE Paraguay (valid until June 2029).

Auditor Opinion

Auditors P. Murali & Co. issued an unqualified opinion on the financial statements and confirmed that the company maintained adequate internal financial controls over financial reporting that were operating effectively as of March 31, 2026.

Forward Outlook

The company aims to convert investments in people, technology, and infrastructure into sustainable CRO revenue growth over the next 2-3 years, focusing on higher-value GLP-compliant programs and expansion of swine and non-human primate facilities.